Revenue
2021
2022
2023
2024
2025
2026
Virax Biolabs Group Ltd (VRAX)
Price$2.85Cached quote
Net income
2021
2022
2023
2024
2025
2026
Free cash flow
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue | $12,423 | $6,331 | $156,419 | $8,561 | $0 | $123,820 |
| Gross profit | $7,690 | −$53,067 | $50,590 | −$1,365 | — | −$9,434 |
| Gross margin | 61.90% | −838.21% | 32.34% | −15.94% | — | −7.62% |
| Research & development | $3.7M | $1.8M | $1.6M | $2.2M | $433,743 | $120,221 |
| Operating expenses | $6.4M | $6.1M | $6.5M | $5.7M | $1.7M | $635,104 |
| Operating income | −$6.4M | −$6.2M | −$6.5M | −$5.7M | −$1.7M | −$644,538 |
| Operating margin | −51,515.17% | −97,344.76% | −4,153.25% | −66,963.68% | — | −520.54% |
| EBITDA | −$5.4M | −$5.9M | −$6.4M | −$5.7M | −$1.7M | — |
| EBITDA margin | −43,722.40% | −93,133.72% | −4,118.17% | −66,963.68% | — | — |
| Net income | −$5.0M | −$6.1M | −$6.7M | −$5.5M | −$1.7M | −$672,915 |
| Net profit margin | −40,439.10% | −95,833.71% | −4,308.38% | −63,751.47% | — | −543.46% |
| Basic EPSper basic share | -$12.64 | -$1.62 | -$3.36 | -$5.13 | -$1.79 | — |
| Diluted EPSper diluted share | -$12.64 | -$1.62 | -$3.36 | -$5.13 | -$1.79 | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Foster James Alexander Cunliffe | 287.99K |
JANE STREET GROUP, LLC | 26.39K |
UBS Group AG | 4 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data